150
Participants
Start Date
October 31, 2025
Primary Completion Date
April 30, 2029
Study Completion Date
February 28, 2034
Teclistamab
Teclistamab will be administered via a subcutaneous injection (SC), fixed duration and will be retreated until disease progression or intolerable toxicity.
Talquetamab
Talquetamab will be administered via a subcutaneous injection (SC), fixed duration and will be retreated until disease progression or intolerable toxicity.
Daratumumab
Dartumumab will be administered via a subcutaneous injection (SC), fixed duration and will be retreated until disease progression or intolerable toxicity.
EMN Trial Office S.r.l. Impresa Sociale
OTHER
HOVON - Dutch Haemato-Oncology Association
OTHER
PETHEMA Foundation
OTHER
Nordic Myeloma Study Group
OTHER
Janssen Pharmaceutica N.V., Belgium
INDUSTRY
European Myeloma Network B.V.
NETWORK